Filing Flows › PAVmed (PAVM) › Q1 2026
PAVmed (PAVM) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
PAVmed (PAVM) reported revenue of $22K for the first quarter 2026 (Q1 2026), +175% from a year earlier and -58% from the quarter before.
PAVmed, Q1 2026: revenue $22K (+175% year over year), net loss $1.1M, operating cash flow −$2.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22K | -58% | +175% |
| Operating profit | −$8.0M | — | — |
| Net earnings | −$1.1M | — | -106% |
| Operating cash flow | −$2.6M | — | — |
What changed
Revenue was $22K in Q1 2026, up 175% year over year and down 58% from the previous quarter.
Operating costs exceeded revenue by $8.0M, an operating margin of -36522.7%. Total costs grew 48% against revenue growth of 175%. The fastest-growing cost line was Cost of revenue (+169%). The quarter ended with a net loss of $1.1M, narrower than the previous quarter's $2.8M loss. Minority interests bore $1.0M of it: to shareholders the quarter was a loss of $60K. Non-operating items added $7.0M, -655% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$2.6M. Non-cash charges added back $20K of depreciation and amortization and $182K of share-based compensation. Working capital and other items used $1.8M. Capital expenditures of $22K exceeded it, leaving free cash flow of −$2.6M.
Questions
What was PAVmed's revenue in the first quarter 2026?
PAVmed (PAVM) reported revenue of $22K for the first quarter 2026 (Q1 2026), +175% from a year earlier and -58% from the quarter before.
Source: PAVmed 10-Q on SEC EDGAR.